U.S. congressional committee members warned that Washington’s funding of the World Health Organization’s cancer research agency could be halted unless it is more open about its operations.
Eli Lilly & Co.’s Cyramza met the main study goal but failed to improve survival rates in a late-stage trial for gastric cancer.
With one year of operations now under its belt since the grand opening, pharma giant GlaxoSmithKline has a bold future planned for its research and development facility in Maryland.
Denali Therapeutics – launched in May 2015 by three former Genentech researchers – went public, raising $250 million with shares priced at $18.
Pfizer’s talazoparib for advanced breast cancer was demonstrated to be superior to chemotherapy in a late-stage study.
The Philippines will seek the return of 3 billion pesos ($59 million) it paid French drugmaker Sanofi for a dengue vaccine used to immunize hundreds of thousands of children that Sanofi has said could worsen the disease in some cases.
Roche scientists may have discovered why some tumors resist new immunotherapy drugs as well as a possible means of turning the tables to incite a T-cell attack.
Gilead Sciences and its cell therapy subsidiary Kite Pharma agreed to acquire Cell Design Labs.
San Diego’s Halozyme Therapeutics tied up a licensing agreement with Connecticut-based Alexion Pharmaceuticals that could net the company $680 million.
Philadelphia-based Spark Therapeutics, with its partner Pfizer, published interim data from its Phase I/II clinical trial of a gene therapy for hemophilia B in The New England Journal of Medicine.